Safety of Long-Term Growth Hormone Treatment Assessed
A team of investigators evaluated the safety of long-term growth hormone replacement treatment in individuals with growth hormone deficiency.
A team of investigators evaluated the safety of long-term growth hormone replacement treatment in individuals with growth hormone deficiency.
Researchers discussed challenges and preventive strategies for clinicians to detect and manage patients with mild TBI-induced growth hormone deficiency.
A team of investigators sought to determine the incidence of infants born small for gestational age and assess the timing of their catch-up growth.
Study authors assessed the long-term effectiveness and safety of GH in real-life clinical practice and whether age mattered at the time of treatment initiation.
There has been a significant surge in the use of growth hormone to improve athletic ability and combat aging despite no clear supporting evidence.
Patient evaluation, follow-up testing, and treatment differ based on lesion size and presence of hormone abnormalities with pituitary incidentalomas.
Switching from daily human growth hormone to once-weekly TransCon growth hormone treatment resulted in similar safety and efficacy outcomes in pediatric patients.
The FDA has granted Orphan Drug designation to TransCon hGH (lonapegsomatropin; Ascendis Pharma), a long-acting prodrug of somatropin, for the treatment for growth hormone deficiency.
A once-weekly growth hormone replacement therapy demonstrated superiority over placebo for patients with adult growth hormone deficiency.
Growth hormone replacement can raise irisin levels in children with growth hormone deficiency.